{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:11Z","timestamp":1780920671630,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":91,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101196","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:57:50Z","timestamp":1775231870000},"page":"101196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pertuzumab\u2013Docetaxel\u2013Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India"],"prefix":"10.1016","volume":"47","author":[{"given":"Ajay","family":"Gogia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"K Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra P","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Krishna Raju","family":"Sagiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101196_bib0001","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0002","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101196_bib0004","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12885-022-09578-1","article-title":"Burden of cancers in India- estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National cancer registry program","volume":"22","author":"Kulothungan","year":"2022","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101196_bib0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ctarc.2026.101196_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1446414","article-title":"HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CE.S217848","article-title":"Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy","volume":"14","author":"Ishii","year":"2019","journal-title":"Core Evid."},{"key":"10.1016\/j.ctarc.2026.101196_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101196_bib0009","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0011","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0012","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-024-13035-6","article-title":"Estimation of burden of cancer incidence and mortality in India: based on global burden of disease study 1990\u20132021","volume":"24","author":"Jena","year":"2024","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101196_bib0013","first-page":"58","article-title":"Cancer in the elderly in India: challenges, attitudes, and strategies for improvement","volume":"11","author":"Mahani","year":"2024","journal-title":"Ann. Geriatr. Educ. Med. Sci."},{"key":"10.1016\/j.ctarc.2026.101196_bib0015","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3390\/jcm13071873","article-title":"Hormone receptor-positive\/HER2-positive breast cancer: hormone therapy and anti-HER2 treatment: an update on treatment strategies","volume":"13","author":"Tommasi","year":"2024","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101196_bib0016","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","article-title":"Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy","volume":"21","author":"Giuliano","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101196_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2026.101196_bib0018","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0019","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101196_bib0020","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4143\/crt.2021.1103","article-title":"Real-world evidence of trastuzumab, pertuzumab, and docetaxel combination as a first-line treatment for Korean patients with HER2-positive metastatic breast cancer","volume":"54","author":"Lee","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101196_bib0021","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/OP.22.00565","article-title":"Real-world first-line use of pertuzumab with different taxanes for human epidermal growth factor receptor 2\u2013positive metastatic breast cancer: a comparative effectiveness study using US electronic health records","volume":"19","author":"Polito","year":"2023","journal-title":"JCO Oncol. Pr."},{"key":"10.1016\/j.ctarc.2026.101196_bib0022","author":"Ferlay"},{"key":"10.1016\/j.ctarc.2026.101196_bib0023","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: result from national cancer registry programme, India","volume":"156","author":"Sathishkumar","year":"2022","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ctarc.2026.101196_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103835","article-title":"Current and future burden of breast cancer in Asia: a GLOBOCAN data analysis for 2022 and 2050","volume":"79","author":"Fu","year":"2025","journal-title":"Breast"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:46:07Z","timestamp":1780919167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"alternative-id":["S2468294226001073"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101196","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pertuzumab\u2013Docetaxel\u2013Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101196"}}